Searching for a cure, Improving lives

Sarconeos announced as new potential treatment for Duchenne

Posted on: September 11th, 2017 | 0 comments

Biophytis clinical stage drug-candidate Sarconeos demonstrates efficacy in preclinical models of Duchenne muscular dystrophy

An abstract entitled “Sarconeos demonstrates sharp functional improvement and anti-fibrotic properties in an animal model of Duchenne muscular dystrophy” has been selected for presentation at the World Muscle Society international congress being held on 3-7 October 2017 in St Malo, France.

Stanislas Veillet, CEO of Biophytis said: “The abstract highlights exciting data demonstrating Sarconeos’ potential ability to improve muscle function not only in sarcopenia but also in other neuro-muscular diseases, such as Duchenne. Duchenne muscular dystrophy is a debilitating progressive disease with few treatment options for patients. Sarconeos’ oral delivery and safety profile could offer a promising treatment alone or combined with gene therapies when they become available. We are now designing the possible clinical roadmap for this new Orphan indication, which offers a clear regulatory pathand accelerated timelines to market.”

About the Sarconeos study

In the study, mdx mice were treated daily with either Sarconeos for 8 weeks. At completion of the study, mice treated with Sarconeos showed statistically significant improvements in running distances (2.4-fold) when compared to untreated mdx mice. Additionally, the treated mice showed improvements in maximal muscle force of 15% when treated with Sarconeos. Gene expression markers in the heart for fibrosis (CTGF) and hypertrophy (my7, BMP4) were reduced in treated mice, and histopathological analysis revealed a clear decrease of muscle lesion profile, as well as a decrease in fibrosis in the treated mdx animals.

These results demonstrate the efficacy of Sarconeos in the improvement of dystrophic muscle functionality and in the prevention of fibrosis appearance and potentially open a new therapeutic option for people living with Duchenne.

Join us at the Action Duchenne International Conference to hear up to the minute news and developments in international Duchenne research. 

Get involved in Action Duchenne

 

Leave a Reply

Your email address will not be published. Required fields are marked *

Donate

Support Action Duchenne with a monthly or one off donation

Donate

Events

View our events

View All Events

Registry

Join the DMD registry for access to clinical trials

Register

Action Duchenne launches new Research Strategy for Duchenne muscular dystrophy

November 17th, 2017

  Action Duchenne, a leading UK-wide patient and parent-led organisation for Duchenne Muscular Dystrophy, is

Tell me more

Final agenda for Action Duchenne International Conference released!

November 1st, 2017

We are delighted to bring you the world’s experts in Duchenne for the 15th year

Tell me more

Long-term microdystrophin pre-clinical work, moving towards a potential therapy restores muscle function in canines

July 26th, 2017

Promising microdystrophin pre-clinical work, moving towards a potential therapy has shown to restore muscle function

Tell me more

Action Duchenne are developing a set-up fund for adult Duchenne muscular dystrophy trials

November 8th, 2017

By Dr Ros Quinlivan, University College London Here at the National Hospital for Neurology and

Tell me more

Report on the delivery of an extension Transition Project to support families of boys with Duchenne in Morpeth 2017

November 8th, 2017

By Celine Barry, Takin’ Charge Co Founder From May to October 2017, I have worked

Tell me more

Duchenne – How do you measure a life?

Living with Duchenne – an animation

Taking charge of Duchenne

wordpress counter

Stay informed with regular updates from Action Duchenne